S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Cardlytics Stock Forecast, Price & News

-2.08 (-3.30%)
(As of 01/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
264,489 shs
Average Volume
358,746 shs
Market Capitalization
$2.03 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardlytics and its competitors with MarketBeat's FREE daily newsletter.

Cardlytics logo

About Cardlytics

Cardlytics, Inc. engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded by Scott D. Grimes, Lynne M. Laube, and Hans Theisen on June 26, 2008 and is headquartered in Atlanta, GA.


See More Headlines

Industry, Sector and Symbol

Computer programming, data processing, & other computer related
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$186.89 million
Book Value
$5.72 per share


Net Income
$-55.42 million
Pretax Margin




Free Float
Market Cap
$2.03 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.25 out of 5 stars

Business Services Sector

116th out of 450 stocks

Computer Programming, Data Processing, & Other Computer Related Industry

17th out of 90 stocks

Analyst Opinion: 3.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

Is Cardlytics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cardlytics stock.
View analyst ratings for Cardlytics
or view top-rated stocks.

How has Cardlytics' stock price been impacted by Coronavirus?

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CDLX stock has increased by 33.1% and is now trading at $60.98.
View which stocks have been most impacted by COVID-19

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Cardlytics

How were Cardlytics' earnings last quarter?

Cardlytics, Inc. (NASDAQ:CDLX) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.02. The company earned $64.98 million during the quarter, compared to analyst estimates of $62.40 million. Cardlytics had a negative net margin of 50.59% and a negative trailing twelve-month return on equity of 13.92%.
View Cardlytics' earnings history

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $247.10 million-$257.10 million, compared to the consensus revenue estimate of $253.46 million.

What price target have analysts set for CDLX?

5 analysts have issued 1-year price targets for Cardlytics' shares. Their forecasts range from $100.00 to $150.00. On average, they anticipate Cardlytics' stock price to reach $129.67 in the next twelve months. This suggests a possible upside of 112.6% from the stock's current price.
View analysts' price targets for Cardlytics
or view top-rated stocks among Wall Street analysts.

Who are Cardlytics' key executives?

Cardlytics' management team includes the following people:

What is Scott Grimes' approval rating as Cardlytics' CEO?

63 employees have rated Cardlytics CEO Scott Grimes on Glassdoor.com. Scott Grimes has an approval rating of 86% among Cardlytics' employees.

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Square (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), Walt Disney (DIS), Alibaba Group (BABA), Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

When did Cardlytics IPO?

(CDLX) raised $76 million in an initial public offering (IPO) on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.78%). Company insiders that own Cardlytics stock include Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, S Aimee Lapic, Scott D Grimes, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics

Which major investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC. Company insiders that have sold Cardlytics company stock in the last year include Andrew Christiansen, Kirk Somers, Lynne Marie Laube, S Aimee Lapic, and Scott D Grimes.
View insider buying and selling activity for Cardlytics
or view top insider-selling stocks.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $60.98.

How much money does Cardlytics make?

Cardlytics has a market capitalization of $2.03 billion and generates $186.89 million in revenue each year. The company earns $-55.42 million in net income (profit) each year or ($3.87) on an earnings per share basis.

How many employees does Cardlytics have?

Cardlytics employs 471 workers across the globe.

What is Cardlytics' official website?

The official website for Cardlytics is www.cardlytics.com.

Where are Cardlytics' headquarters?

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at (888) 798-5802 or via email at [email protected].

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.